IGCPharma showcases AI innovations for Alzheimer's detection and drug discovery at 2025 conference.

IGCPharma unveiled three AI-powered scientific posters at the 2025 Alzheimer's Association International Conference, showcasing breakthroughs in drug discovery and early Alzheimer's detection. Their MINT-AD model assesses Alzheimer's risk and forecasts cognitive decline, while large language models predict cognitive scores using socioeconomic data. IGC's AI-driven drug discovery pipeline optimizes molecule interactions with Alzheimer's targets, potentially accelerating future research and treatment development.

Title: IGC Pharma Unveils AI-Powered Breakthroughs at 2025 Alzheimer's Association International Conference

IGC Pharma (NYSE American: IGC), a clinical-stage biopharmaceutical company specializing in Alzheimer's disease research, presented three scientific posters at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025. The company showcased advanced AI platforms designed to accelerate drug discovery and improve early detection of Alzheimer's disease, particularly in low-resource settings.

The first poster, titled "Multimodal Interpretable Transformer for AD (MINT-AD)," introduced an AI foundation model trained on over 100 globally diverse datasets to stratify Alzheimer's risk and forecast cognitive decline. Designed to empower general practitioners, MINT-AD integrates clinical, demographic, and lifestyle data to produce personalized, interpretable Alzheimer's risk assessments and predict cognitive decline [1].

Another poster, "MINT-AD: Early Prediction of MMSE & CSI-D Scores with AI," highlighted research demonstrating the use of large language models (LLMs) to accurately predict Mini Mental State Exam (MMSE) and Community Screening Instrument for Dementia (CSI-D) cognitive scores using socioeconomic data alone. This approach offers a highly scalable and accessible method to support clinicians in predicting cognitive decline trajectories and guiding early interventions [1].

The third poster, "AI in the Drug Discovery Pipeline," detailed IGC's hybrid in-silico and in-vitro pipeline, which utilizes AI-powered screening models to rapidly identify and optimize interactions between proprietary molecules and Alzheimer's-relevant targets, including GLP-1 and CB1. The results demonstrate significant promise for accelerating future in vitro validation and compound optimization efforts in Alzheimer's disease discovery [1].

IGC Pharma's CEO, Ram Mukunda, expressed excitement about the company's AI innovations, stating, "We are excited to share our latest AI innovations at AAIC 2025, which underscore IGC's commitment to transforming Alzheimer's care and research. Our cutting-edge deep learning techniques are designed to expand access to earlier diagnosis and accelerate the discovery of effective therapeutics by leveraging diverse, real-world datasets. Showcasing this research at the AAIC is a pivotal step as we establish IGC as a leader in applying AI to precision medicine in Alzheimer's, strengthening our scientific foundation and streamlining drug development" [1].

IGC Pharma's lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The company's pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. IGC Pharma integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting [1].

The presentations at AAIC 2025 are a significant milestone for IGC Pharma, highlighting their commitment to innovation and the potential of AI in transforming Alzheimer's research and treatment.

References:
[1] https://www.stocktitan.net/news/IGC/igc-pharma-to-present-advanced-ai-platforms-for-alzheimer-s-disease-i5upvjh8efwt.html
[2] https://finance.yahoo.com/news/igc-pharma-present-advanced-ai-130000805.html